Several leading medical organizations have released updated recommendations for flu, COVID-19, and respiratory syncytial virus (RSV) vaccines for the 2026-27 respiratory season. The guidance, available through the Vaccine Integrity Project, is especially important for people with multiple myeloma, who may have a higher risk of serious infections.

Myeloma causes abnormal plasma cells to build up in the bone marrow. These cells can make abnormal proteins and reduce the body’s ability to produce normal antibodies that fight infection.

Some myeloma treatments also can weaken immune defenses. For people with myeloma, these factors can increase the risk of serious infection from viruses.

🗳️ Have you spoken with your doctor about COVID-19, flu, or RSV vaccinations for 2026-2027?

Yes, and it was helpful.

Yes, but it wasn’t helpful.

No, but I plan to.

No, and I don’t plan to.

Thanks! You've successfully submitted your vote.

Sign up to view the results!

Continue with Facebook

Continue with Google

Continue with Email

By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.

Already a member? Log In

Vaccines train the immune system to recognize and fight specific viruses. This can help your body respond more quickly if you’re exposed to them.

There isn’t one vaccine plan that’s right for everyone with myeloma. Your age, treatment plan, immune function, vaccination history, and other health conditions can all influence which vaccines are recommended and when you should receive them.

The Vaccine Integrity Project, working with the American Medical Association, reviewed the latest evidence on flu, COVID-19, and RSV immunizations for the 2026-27 respiratory season. The findings helped inform recommendations from several leading medical organizations, including:

The review included 299 studies published mostly between August 2025 and June 2026. It found that flu, COVID-19, and RSV immunizations continued to provide meaningful protection against hospitalization, severe illness, and death.

The amount of protection can vary based on the virus, the vaccine or immunization, the season, and a person’s health. For people with multiple myeloma, vaccination decisions should take into account factors such as age, treatment, and immune function.

For the 2026-27 respiratory season, COVID-19 and flu vaccines have updated formulations. There are also three RSV vaccines for adults. These vaccines differ in how they are made and which age groups or risk groups they are approved for.

COVID-19 Vaccines

The U.S. Food and Drug Administration (FDA) has approved four COVID-19 vaccine options. All four vaccines are given by injection.

The IDSA recommends that people with weakened immune systems discuss receiving a second dose of the COVID-19 vaccine two to six months after the first dose.

Flu Vaccines

All U.S. flu vaccines for the 2026-27 season are trivalent, meaning they are designed to protect against three influenza viruses.

Most people need one flu vaccine dose each season. Some children may need a second dose based on their age, vaccination history, or individual health circumstances. For people with multiple myeloma, the timing of the flu vaccine may need to be coordinated with treatment.

People who are immunocompromised shouldn’t receive the live-attenuated nasal flu vaccine FluMist, per guidance from the U.S. Centers for Disease Control and Prevention (CDC) and IDSA.

RSV Vaccines

There are three FDA-approved adult RSV vaccines.

For adults, the CDC recommends a single dose of RSV vaccine for everyone age 75 and older and for adults ages 50 through 74 who are at increased risk of severe RSV illness. For people with weakened immune systems, including those with multiple myeloma, the IDSA recommends RSV vaccination starting at age 18. The RSV vaccine isn’t currently given every year.

For people who are immunocompromised, the benefits of vaccination generally outweigh the risks. Current evidence shows that flu, COVID-19, and RSV immunizations can reduce hospitalization, severe illness, and death. People with weakened immune systems may not respond as strongly to vaccines, but vaccination can still provide protection.

Vaccines can cause side effects, but serious side effects are uncommon. Your healthcare team can explain what to expect and help you weigh the benefits and risks based on your:

The right vaccine and timing can vary for people with multiple myeloma. The disease can interfere with normal antibody production, and some treatments can further suppress the immune system.

It’s important to ask not only which products are available, but which type, dose, and timing make sense for you.

Your healthcare team may consider:

Timing Around Treatments

Timing may also matter. The American Society of Clinical Oncology recommends getting vaccinated two to four weeks before planned cancer treatment when possible. However, nonlive vaccines can also be given during or after chemotherapy, immunotherapy, radiation, or surgery.

For people with blood cancers such as multiple myeloma, the IDSA recommends coordinating vaccination with treatment cycles when possible. People who have had a stem cell transplant or CAR T-cell therapy may need a different vaccination schedule.

Your oncology team can recommend the best timing based on your treatment and immune function. Don’t delay, skip, or change myeloma treatment to get vaccinated unless your oncology team recommends it.

People with weakened immune systems may not develop as strong a response to vaccines as people with healthy immune systems. That doesn’t mean vaccination has no benefit.

The Vaccine Integrity Project found that respiratory-virus immunizations continued to reduce severe outcomes among people with immunocompromising conditions, although protection varied.

In many cases, COVID-19, flu, and RSV vaccines can be given at the same visit.

Whether that makes sense for you may depend on your treatment schedule, previous vaccinations, expected side effects, and other health needs. Ask your oncology team whether getting more than one vaccine at the same appointment is appropriate.